EXOME: Biotech • Healthcare • Life Sciences

National
Agenda and Speakers Announced for Xcelerating Life Sciences San Diego

Boston
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
Boston
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH
Boulder/Denver
BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely

1.
Spring Bank Pharma Ends Hepatitis B Work After Death in Clinical Trial | Boston
2.
Agenda and Speakers Announced for Xcelerating Life Sciences San Diego | National
3.
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus | Boston
4.
Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets | San Diego
5.
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Boston
6.
BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Boulder/Denver

Learn about the Xconomists →

Bryony Winn

Bryony Winn

Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina

Digital Health Survivors & Innovative Incumbents Must Team Up for True Disruption

Rob Coppedge

Rob Coppedge

CEO of Echo Health Ventures

Partner or Die: How to Succeed Even After the Digital Health Hype Quiets Down

More Opinion, Insight, and Analysis ›

Xcelerating Life Sciences San Diego

March 18, 2020

$50M

Quench Bio

Passage Bio Appoints Deerfield Management’s Bruce Goldsmith as CEO

Beam Therapeutics Promotes Giuseppe Ciaramella to President

Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report
Gareth Macdonald | National
Flagship Adds Fertility-Focused Ohana Biosciences to Biotech Family
Sarah de Crescenzo | Boston
Quench Bio Springs From Atlas With $50M for a New Take on Inflammation
Frank Vinluan | Boston
Life Sciences IPOs Target Collective Raise of More Than $600M This Week
Sarah de Crescenzo | National
Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie
Frank Vinluan | National
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More
Sarah de Crescenzo | National
Epizyme’s Soft Tissue Cancer Drug Granted Speedy FDA Approval
Frank Vinluan | Boston
After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune
Mike Ward | National
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs
Frank Vinluan | Boston

Read More Posts ›

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Digitizing 10 Life Sciences Paper Processes
How to accelerate your life sciences business with every agreement
DocuSign

Sponsored · Whitepaper
Time Savings That Speed up Science
Monitor spending and save meaningful dollars with life sciences-specific rewards
Brex

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

Xconomy on Demand

We offer a number of ways to subscribe for free!